Copyright
©2014 Baishideng Publishing Group Inc.
World J Hepatol. Sep 27, 2014; 6(9): 670-676
Published online Sep 27, 2014. doi: 10.4254/wjh.v6.i9.670
Published online Sep 27, 2014. doi: 10.4254/wjh.v6.i9.670
Table 2 Sorafenib-related adverse events n (%)
| Adverse events | Any Grade | Grade 1 | Grade 2 | Grade 3 |
| Anorexia | 29 (78) | 8 (22) | 10 (27) | 11 (30) |
| Skin toxicitya | 27 (73) | 6 (16) | 8 (22) | 13 (35) |
| Fatigue | 23 (62) | 3 ( 8) | 11 (30) | 9 (24) |
| Diarrhea | 20 (54) | 9 (24) | 8 (21) | 3 (8) |
| Hypoalbuminemia | 19 (51) | 4 (11) | 14 (38) | 1 (3) |
| Weight loss | 17 (46) | 7 (19) | 9 (24) | 1 (3) |
| Hyperbilirubinemia | 16 (43) | 10 (27) | 5 (14) | 1 (3) |
| Decreased platelet count | 14 (38) | 3 (8) | 9 (24) | 2 (5) |
| Hypertension | 13 (35) | 2 (5) | 6 (16) | 5 (14) |
| Alopecia | 13 (35) | 5 (14) | 8 (22) | 0 (0) |
| Anemia | 9 (24) | 4 (11) | 4 (11) | 1 (3) |
- Citation: Shomura M, Kagawa T, Shiraishi K, Hirose S, Arase Y, Koizumi J, Mine T. Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma. World J Hepatol 2014; 6(9): 670-676
- URL: https://www.wjgnet.com/1948-5182/full/v6/i9/670.htm
- DOI: https://dx.doi.org/10.4254/wjh.v6.i9.670